Episurf — Regulatory Filings 2016

Jan 18, 2016

Company Announcement January 18, 2016

Episurf Medical launches German website and increases marketing efforts in the region

In line with planned expansion in the German market, Episurf Medical has launched its German website. The new website is aimed to support the company's accelerated penetration plans in the region and further enable Episurf Medical to reach out with information specifically targeted to German-speaking physicians and prospective patients.

"Germany is one of our key markets and the European country where most knee related surgical interventions are performed. We have received excellent feedback from German surgeons about our intelligent, patient specific implant technology and are excited to provide German customers and new users with even better service through specific German language information," says Rosemary Cunningham Thomas, CEO, Episurf Medical.

In 2015, Episurf Medical made key recruitments to establish the core German sales organisation, which is expected to grow with four additional sales representatives in 2016.

The website can be reached directly from www.episurf.de as well as a direct link on the www.episurf.com website.

For more information, please contact:

Rosemary Cunningham Thomas, CEO, Episurf Medical Tel: +46 (0) 70-7655892 Tel: +44 (0) 7803-753603 rosemary@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical's Episealer® personalized implants and Epiguide® surgical drill guides are in development for treating localized cartilage injury in joints. Episurf Medical's μiFidelity® system will enable implants to be costefficiently tailored to each individual's unique injury for the optimal fit and minimal intervention.

Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com. The information in this press release is such that Episurf Medical AB is required to disclose in accordance with the Securities Markets Act and/or the Financial Instruments Trading Act.